EVP, Operations · Amgen Inc. (AMGN)

Esteban Santos

A named executive officer of Amgen in every fiscal year CompBrief holds from FY2020 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$7,205,836

Salary $1,061,385Stock awards $2,939,776

FY2021: $7,362,633

5th of 5 named executive officers at Amgen by FY2023 total.

5 named officers on file for Amgen, FY2023

Esteban Santos’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 9 equity grants, each cited to its filing
  • AMGN’s disclosed peer group of 15 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Amgen’s whole pay program stands against its peers

  • Amgen’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on AMGN→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 17, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Esteban Santos’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Esteban Santos compensation by year

Amgen Summary Compensation Table · all 3 fiscal years held
In US dollars, as Amgen reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021FY2023
Salary$978,446$994,246$1,061,385
Bonus$0$0$0
Stock awards$2,799,625$3,324,824$2,939,776
Option awards$1,199,958$1,424,988$1,259,986
Non-equity incentive$1,384,000$1,354,000$1,688,000
Pension and deferred compensation$0$0$0
All other$229,624$264,575$256,689
Total$6,591,653$7,362,633$7,205,836

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Amgen Inc. DEF 14A filed April 17, 2024, accession 0001193125-24-099062, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Amgen Inc. filed document, accession 0001193125-24-099062. Every figure is read from that document and cited to the page and table it appears in. Filed April 17, 2024.

$6.6M
$7.4M
$7.2M
FY20
FY21
FY23
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
PSU17,068$4,915,925—
PSU12,278$3,536,310—
RSU11,701$3,370,122—
PSU8,987$2,588,436—
Option30,100—$235.97
Option29,695—$230.92
Option9,636—$236.36
Option23,062—$239.64

Per the Outstanding Equity Awards at Fiscal Year-End table in Amgen Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

29 Form 4 lines since the FY2023 proxy (filed April 17, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-05-07Tax withholding—522$331.1182,847
2026-05-06Tax withholding—427$329.5983,369
2026-05-05Grant or award derivative—17,814$329.5917,814
2026-05-05Grant or award—2,730$0.0083,796
2026-05-02Tax withholding—641$329.8281,066
2026-05-02Tax withholding—697$329.8281,707
2026-03-16Tax withholding—5,621$366.2182,404
2026-03-03Grant or award—11,259$0.0087,877

The 8 most recent of 29 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Change-in-control & termination

estimated payments Amgen discloses, by trigger · FY2023
TriggerCash severanceAccelerated equityBenefits continuationTotal as disclosed
Change in control and involuntary termination$4,269,600$13,682,407$51,473$18,535,440
Retirement$0$13,022,899$0$13,022,899
Disability$0$13,022,899$0$13,022,899
Change in control, no termination$0$6,586,153$0$6,586,153
Death$0$13,022,899$0$13,022,899

Per the Potential Payments Upon Termination or Change in Control table in Amgen Inc.'s FY2023 proxy. Estimates as the company printed them; a dash means it printed no figure.

Amgen’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Robert A. BradwayChief Executive Officer and President$22,643,650
Murdo GordonExecutive Vice President, Global Commercial Operations$8,242,811
David M. ReeseExecutive Vice President and Chief Technology Officer$7,902,655
Peter H. GriffithExecutive Vice President and Chief Financial Officer$7,569,298
Esteban Santos · this pageEVP, Operations$7,205,836

The full Amgen compensation record

free company brief

This page is one person within Amgen's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Amgen proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Amgen's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Esteban Santos's compensation dossier · One-time report. No refunds.